Scientific Sessions 2024  /  New Targets and New Treatments: Advances in Lipid Therapeutics  /  Discussant: CETP inhibition-is it time for a revival?
Logo

American Heart Association

  155
  0

Final ID:

Discussant: CETP inhibition-is it time for a revival?

  • Watson, Karol  ( UCLA , Redondo Beach , California , United States )
    • Author Disclosures:
    KAROL WATSON: DO have relevant financial relationships ; Advisor:amgen:Active (exists now) ; Consultant:novartis:Active (exists now) ; Consultant:boehringer engelheim:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Targets and New Treatments: Advances in Lipid Therapeutics

Monday, 11/18/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:
A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles

Nicholls Stephen, Ni Wei, Rhodes Grace, Nissen Steven, Navar Ann Marie, Michael Laura, Krege John

Discussant: Lipoprotein a therapeutics, understanding the pipeline

Tokgozoglu Lale, Goldberg Anne

More abstracts from these authors:
2025 AHA/ACC BP Guideline: The 12 Key Takeaways You Can't Miss

Watson Karol

Don't Let Up: An Ounce of Prevention is Worth a Pound in Cardio-Oncology

Watson Karol, Lloyd-jones Donald

You have to be authorized to contact abstract author. Please, Login
Not Available